Fiasp® 100IU/ml Solution for Injection is used for blood sugar control in people with type 1 and type 2 diabetes. It helps lower blood sugar level after meals and further reduces the chance of developing any diabetes complications which include kidney damage, nerve problems, loss of limbs or eye damage.
Your doctor may prescribe Fiasp® 100IU/ml Solution for Injection to be used with a long-acting type of insulin or other medications for diabetes.
Fiasp® (insulin aspart) vials is a fast-acting type of insulin that closely matches the natural physiological insulin produced after a meal by a person who doesn’t have diabetes. To increase the speed of absorption, Fiasp® has included Vitamin B3 (niacinamide) and for stability, L-Argenine which is a natural amino acid.
Unlike other common brands of insulin, Fiasp® has a more flexible dosing regimen that allows you to inject up to 2 minutes prior to starting a meal or up to 20 minutes after starting a meal without compromising your overall safety and glycemic control.
In order to reduce the progression of diabetes related complications, Diabetes Canada recommends achieving optimal glycemic control.
Fiap insulin absorbs twice as fast when compared to NovoRapid (NovoLog), a conventional insulin aspart, after injection before achieving glycemic control after a meal.
Your physician or nurse will instruct you on how to properly inject it subcutaneously (under the skin).
Fiasp® insulin should be taken 15 minutes before your meal or within 20 minutes of starting a meal. It’s important to monitor your blood glucose levels regularly and keep track of results. Share your results with your doctor so that they can prescribe the correct dose that works for you.
Unless your doctor tells you otherwise, do not stop taking this medication.
Taking this diabetes medication should be part of your treatment along with a healthy diet, exercise program and weight loss plan as advised by your doctor.
Pump or infusion set malfunctions can potentially lead to a rapid onset of hyperglycemia or ketoacidosis. Interim therapy with subcutaneous injection of Fiasp®® may be required. Patients using continuous subcutaneous insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure.
Patients should rotate injection areas to avoid lipodystrophy or localized cutaneous amyloidosis.
Do not share needles or pens with others as this can lead to serious health risks such as spreading blood-borne pathogens.
Do not drink alcohol excessively while taking this medication as it can lead to a significant drop in blood sugar levels.
Your ability to operate a vehicle may be impaired if your blood sugar is too high or too low. Do not drive if you are experiencing any symptoms.
If you are pregnant or breastfeeding, you should speak with your doctor to adjust your dosages accordingly.
If you have low blood glucose levels (hypoglycemia) you should not take this medication. Speak with your doctor about any health issues such as liver, kidney or heart problems prior to starting your treatment.
Any modifications to your insulin regimen can lead to hyperglycemia or hypoglycemia. This can include insulin strength, type, injection site or method of injection or manufacturer. You should be under medical supervision for any changes to your insulin regimen with close blood sugar monitoring and frequency.
Like most insulin medications, always inspect the label for instructions before use.
Fiasp® use can lead ot hypokalemia which is life-threatening, followed by ventricular arrhythmia, respiratory paralysis and death. It’s important to monitor potassium levels to measure risk for hypokalemia and treat as advised.
Heart failure and fluid retention may occur when combined with thiazolidinediones (TZDs) which are PPAR-gamma agonists, and insulin , including Fiasp®. If a client is experiencing heart failure then dosage reduction or discontinuation may be advised by your doctor.
NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.
While most side effects do not require medical attention, if you do experience any side effects related to taking Fiasp® insulin you should consult a medical expert, especially if side effects persist.
Common side effects include:
- Hypoglycemia (low blood sugar level)
- Local injection site reactions such as rashes, lipodystrophy (hard lumps) or pruritus
- Allergic reaction
- Weight Gain
- Redness or swelling
How to Store Fiasp Insulin Vials
Not in use (unopened): If unopened, Fiasp® vials should be stored in a refrigerator (36°F to 46°F [2°C to 8°C]) until expiration date. If unopened but improperly stored outside of refrigerated conditions, begin in-use storage for a maximum of 4 weeks.1
In use (opened): After first use, Fiasp® vials can be stored at room temperature (below 86°F [30°C]) or in the refrigerator (36°F to 46°F [2°C to 8°C]) for a maximum of 4 weeks (28 days).1